Navigation Links
The Asnis III™ Cannulated Screw System

ProductsThe Asnis III™ Cannulated Screw System
Company Stryker Orthopedics
Item The Asnis III™ Cannulated Screw System
Features 
  • Lower Profile Screw Head - Reduces the potential for soft tissue irritation.
  • Broad Range of Implant Sizing - Asnis III™ offers the surgeon a wide choice of sizing (4.0 mm; 5.0 mm; 6.5 mm; 8.0 mm) in partial and full threads.
  • Self-Drilling/Self-Tapping - Provides faster, efficient cutting for ease of insertion; flat tip minimizes potential for soft tissue irritation.
  • Reverse Cutting Flutes - Facilitates screw removal.
    • Description The Asnis III™ Cannulated Screw System has taken the best of the Asnis 2 and TCS Systems and combined them to offer a more complete range of cannulated screws in both titanium and stainless steel.

    The Asnis III™ Cannulated Screw System is designed to optimize surgical outcomes while simplifying procedures. This system incorporates several unique features intended to enhance screw placement along with ergonomically designed instrumentation.

    Dr. Stanley E. Asnis, recognized as the pioneer of cannulated hip screws in the early 1980's, has assisted in bringing this system to market. Nearly twenty years of clinical success have culiminated into the Asnis III™ Cannulated Screw System, which incorporates proven technology in implant materials and design.
    Info Stryker Orthopedics
    Customer Service: (201) 831-5000
    Web site: http://www.stryker.com/orthopaedics/

    Related medicine products :

    1. PHANTOM Absorbable Cannulated Interference Screws
    2. PHANTOM SofThread Cannulated Interference Screws
    3. ADVANTAGE Titanium Cannulated Interference Screws
    4. PROFILE Titanium Cannulated Interference Screws
    5. ABSOLUTE Absorbable Cannulated Interference Screws
    6. Propel Cannulated Interference Screw
    7. BIG ADVANTAGE Cannulated Titanium Interference Screws
    8. Cannulated Interference Screws
    9. 3.0 mm Cannulated Screw and Threaded Washer
    10. Clear-Trac Threaded Cannula with Cannulated Obturator
    11. 4.0 mm and 6.5 mm Cannulated Screws
    ...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
    ...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
    ...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
    ...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
    Medicine Products:
    (Date:12/3/2008)...Health Care,s Women,s Pavilion,( http://www.auror...n and Spa of,New Berlin partnered for a new kind ...hair extensions. , Throughout the month of ...,$15 each at the Aurora Women,s Pavilion in West A... in New Berlin. The profits from these bright litt...
    (Date:12/3/2008)...ecific Gamma Imaging (BSGI) has,equivalent sensit...tients with,inconclusive findings after mammograp...er, according to findings presented today at the a...h America (RSNA). BSGI is a molecular breast,imag...raphy that can identify,lesions independent of ti...
    (Date:12/3/2008)...-FirstCall/ -- MAP,Pharmaceuticals, Inc. (Nasdaq:...participate in a panel discussion titled "Adapting...at the 2008 RBC Capital Markets Healthcare Confere...(ET) in New York City. , A live webcast of ...stor,Relations section of MAP Pharmaceuticals, we...
    (Date:12/3/2008)...d thinner imported from China , , WEDNES...the deadly contamination of the blood thinner hepa...made chemical that was added to batches of the dru..., The crisis, which began last November, result...hs in the United States. The Chinese heparin, cont...
    Breaking Medicine News(10 mins):Health News:Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer 2Health News:Report Confirms Source of Contaminated Heparin 2Health News:Report Confirms Source of Contaminated Heparin 3
    ...ght may be equivalent to losing 4 kilos of load in...teoarthritis of the knee. Researchers from the Wak...y on effects of exercise and weight loss on the os...ted that an average weight loss of 5% of the body ...
    ...t common and deadly cancer worldwide. About 1.4 mi...r out of which // 85% will die before 2010. Habit ...ut it is fastly increasing in low and middle incom...cer occurrence is smoking. Globally smoking relate...
    ...study researchers say the drug orlistat (Xenical) ... without // major side effects in overweight teens...ntestines to absorb fat by up to 30 percent. Howev...rlistat passes through the body without being dige...
    ...ong time had been associated with being effective ...me out in the journal PLoS Medicine reports that s...he study had looked into the studies made assertin... association between vitamin C and common colds do...
    Other Medicine News:Health News:Aggressive Tobacco taxation policy can reduce cigarette smoking, 2
    (Date:12/3/2008)...ll/ -- Sangamo BioSciences, Inc.,(Nasdaq: SGMO ...e on milestones,achieved in 2008 and preview obje...alyst Briefing to be held in New York City today. ...ich Corporation,s Research,Biotech Business Unit ...f the,two companies, collaboration to commerciali...
    (Date:12/3/2008)...-FirstCall/ -- Isis Pharmaceuticals,Inc. (Nasdaq...uticals, Inc.,provided positive survival results ...11 in combination with docetaxel and prednisone ("...isone alone ("the control arm") for first-line,tr...cancer. The current 10.6,month median overall su...
    (Date:12/2/2008)...-FirstCall/ -- Biopure Corporation,(Nasdaq: BPU...search Center,(NMRC) has submitted to the Food an...onal new drug (IND) application to conduct a clini...opure(R) [hemoglobin glutamer - 250 (bovine)],for...patients. The study is,entitled "Operation Restor...
    (Date:12/1/2008)...re/ -- New research has found that the availabilit...T) scanner in an emergency room can significantly ...a potentially life-saving treatment. Results of th...NSMC)-Salem Hospital in Salem, Mass., will be pres...cal Society of North America (RSNA). , , "T...
    Breaking Medicine Technology:Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3Advanced Cell Technologys Dr Robert Lanza Makes List of 100 Most Inspiring People in the Life Sciences Industry 120 1Advanced Cell Technologys Dr Robert Lanza Makes List of 100 Most Inspiring People in the Life Sciences Industry 120 2Advanced Cell Technologys Dr Robert Lanza Makes List of 100 Most Inspiring People in the Life Sciences Industry 120 3YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 1YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 2YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 3YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 4AMDL Announces 2nd Quarter 2007 Operational Results 116 1AMDL Announces 2nd Quarter 2007 Operational Results 116 2Genta Initiates Phase 3 AGENDA Trial of Genasense 28R 29 for Patients with Advanced Melanoma 109 1Genta Initiates Phase 3 AGENDA Trial of Genasense 28R 29 for Patients with Advanced Melanoma 109 2Genta Initiates Phase 3 AGENDA Trial of Genasense 28R 29 for Patients with Advanced Melanoma 109 3Genta Initiates Phase 3 AGENDA Trial of Genasense 28R 29 for Patients with Advanced Melanoma 109 4Genta Initiates Phase 3 AGENDA Trial of Genasense 28R 29 for Patients with Advanced Melanoma 109 5